Pediatric pulmonary hypertension

Hari Rajagopal; Ruchika Karnik; Raj Sahulee

doi:10.1542/pir.2015-0067

Pediatric pulmonary hypertension

Hari Rajagopal, Ruchika Karnik, Raj Sahulee

Research output: Contribution to journal › Comment/debate

3 Scopus citations

Original language	English
Pages (from-to)	129-131
Number of pages	3
Journal	Pediatrics in Review
Volume	37
Issue number	3
DOIs	https://doi.org/10.1542/pir.2015-0067
State	Published - Mar 2016

Access to Document

10.1542/pir.2015-0067

Cite this

@article{0e5f7e7e6a9349c9ad36850eb53ccaec,

title = "Pediatric pulmonary hypertension",

author = "Hari Rajagopal and Ruchika Karnik and Raj Sahulee",

note = "Funding Information: The University of Colorado School of Medicine has received consulting fees for Dr. Ivy from Actelion, Bayer, Gilead, Eli Lilly, Pfizer, and United Therapeutics. The University Medical Center Groningen has received consulting fees for Dr. Berger from Actelion, Bayer, GlaxoSmithKline, Lilly, Novartis, and Pfizer. Dr. Berger has performed consultancies for Actelion, Bayer, GlaxoSmithKline, Lilly, Novartis, Pfizer, and United Therapeutics. Dr. Bonnet has received lecture and consulting honoraria from Actelion, Eli Lilly, Pfizer, and Bayer. Dr. Fleming has served as a consultant to Actelion and Pfizer. Dr. Haworth has received consulting fees from GlaxoSmithKline. Dr. Rosenzweig has received research grant support from Actelion, Gilead, GlaxoSmithKline, Eli Lilly, Bayer, and United Therapeutics ; and consulting honoraria from United Therapeutics and Actelion. The University of California has received consulting fees for Dr. Steinhorn from Ikaria and United Therapeutics, and she has served as an unpaid consultant to Actelion. Dr. Beghetti has served as an advisory board member for Actelion, Bayer, Eli Lilly, GlaxoSmithKline, Novartis, and Pfizer; has received grants from Actelion and Bayer ; has receiving lecture fees from Actelion, Bayer, and Pfizer; has developed educational materials for Actelion and Pfizer; and has receiving consulting fees from Actelion, Bayer, GlaxoSmithKline, Pfizer, and Novartis. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. ",

year = "2016",

month = mar,

doi = "10.1542/pir.2015-0067",

language = "English",

volume = "37",

pages = "129--131",

journal = "Pediatrics in Review",

issn = "0191-9601",

publisher = "American Academy of Pediatrics",

number = "3",

}

TY - JOUR

T1 - Pediatric pulmonary hypertension

AU - Rajagopal, Hari

AU - Karnik, Ruchika

AU - Sahulee, Raj

N1 - Funding Information: The University of Colorado School of Medicine has received consulting fees for Dr. Ivy from Actelion, Bayer, Gilead, Eli Lilly, Pfizer, and United Therapeutics. The University Medical Center Groningen has received consulting fees for Dr. Berger from Actelion, Bayer, GlaxoSmithKline, Lilly, Novartis, and Pfizer. Dr. Berger has performed consultancies for Actelion, Bayer, GlaxoSmithKline, Lilly, Novartis, Pfizer, and United Therapeutics. Dr. Bonnet has received lecture and consulting honoraria from Actelion, Eli Lilly, Pfizer, and Bayer. Dr. Fleming has served as a consultant to Actelion and Pfizer. Dr. Haworth has received consulting fees from GlaxoSmithKline. Dr. Rosenzweig has received research grant support from Actelion, Gilead, GlaxoSmithKline, Eli Lilly, Bayer, and United Therapeutics ; and consulting honoraria from United Therapeutics and Actelion. The University of California has received consulting fees for Dr. Steinhorn from Ikaria and United Therapeutics, and she has served as an unpaid consultant to Actelion. Dr. Beghetti has served as an advisory board member for Actelion, Bayer, Eli Lilly, GlaxoSmithKline, Novartis, and Pfizer; has received grants from Actelion and Bayer ; has receiving lecture fees from Actelion, Bayer, and Pfizer; has developed educational materials for Actelion and Pfizer; and has receiving consulting fees from Actelion, Bayer, GlaxoSmithKline, Pfizer, and Novartis. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

PY - 2016/3

Y1 - 2016/3

UR - https://www.scopus.com/pages/publications/84959328813

U2 - 10.1542/pir.2015-0067

DO - 10.1542/pir.2015-0067

M3 - Comment/debate

C2 - 26933230

AN - SCOPUS:84959328813

SN - 0191-9601

VL - 37

SP - 129

EP - 131

JO - Pediatrics in Review

JF - Pediatrics in Review

IS - 3

ER -